Increasing instances of substandard, falsified and counterfeit medical products continue to pose a major challenge to the global healthcare system which is already suffering from the dire impact of COVID-19. To address this issue, ASPA and Messe Frankfurt India will unite leading experts from
MoreInforma Markets is launching an annual dedicated online platform for pharma in May (17-28th), CPhI Discover – designed to encourage suppliers and customers to
MoreAzelis, an innovation service provider, is excited to release its sustainability strategy, ‘Action 2025’, reinforcing its commitment to become the
MoreThe Japanese pharmaceutical market is preparing for renewed international growth and partnering. In response, CPhI Japan has opened a two-month
MoreWith the acquisition of the Spanish manufacturer STE Tecpharm, S. L., Romaco strengthens its position as a turnkey supplier of
MoreDeutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration
MoreThe leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner Avance Clinical congratulated Atossa
MoreA post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare
MoreI Holland, leaders in the manufacture of tablet tooling for the pharmaceutical and nutraceutical markets, has announced a series of
MoreEisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered
MoreNovartis announced the Health Sciences Authority (HSA) has approved* Piqray®, an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor, for the treatment of
More